Elder Pharma tumbles after company says facing severe financial crunch

Image
Capital Market
Last Updated : Sep 07 2015 | 5:29 PM IST

Elder Pharmaceuticals fell 5.37% to Rs 83.65 at 15:12 IST on BSE after the company said it is facing severe financial crunch and consequently the audit for the financial year ended 30 June 2015 has been delayed.

The announcement was made on Saturday, 5 September 2015.

Meanwhile, the BSE Sensex was down 302.31 points, or 1.20%, to 24,899.59.

On BSE, so far 15,000 shares were traded in the counter, compared with an average volume of 84,309 shares in the past one quarter.

The stock hit a high of Rs 88 and a low of Rs 83.25 so far during the day. The stock hit a 52-week high of Rs 215.55 on 15 September 2014. The stock hit a 52-week low of Rs 66.65 on 10 June 2015.

The stock had underperformed the market over the past one month till 4 September 2015, sliding 23.40% compared with 10.22% fall in the Sensex. The scrip had, however, outperformed the market in past one quarter, rising 27.19% as against Sensex's 6.01% decline.

The small-cap company has an equity capital of Rs 20.54 crore. Face value per share is Rs 10.

Elder Pharmaceuticals' current financial year ended on 30 June 2015. Accordingly, it has to submit quarterly and yearly audited financial results within 60 days from the end of quarter i.e. on or before 29 August 2015.

The company, however, announced that it is facing severe financial crunch, due to which many of its senior employees, including junior and subordinate staff, have resigned from the company. This has led to severe shortage of employees to handle the work of accounts and audit for the same and therefore audit has not completed within time. Therefore, the company was unable to hold the board meeting before 29 August 2015.

The company said it is in process to complete the audit as early as possible and will submit the audited financial results in due course of time.

On consolidated basis, Elder Pharmaceuticals reported net loss of Rs 46.02 crore in Q3 March 2015, lower than net loss of Rs 73.63 crore in Q3 March 2014. Net sales declined 33.5% to Rs 151.30 crore in Q3 March 2015 over Q3 March 2014.

Elder Pharmaceuticals is an integrated pharmaceutical player, headquartered in Mumbai, with a strong presence in the domestic formulation business.

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 07 2015 | 3:14 PM IST

Next Story